Table 4.

Association of IL-12p40 with melanoma-specific survival

Variable	Discovery set(N=573)			Case validation set 1(N=249)			Case validation set 2(N=244)			Pooled results using meta-analysis
	N/Events	HR(95%CI)	P-value	N/Events	HR(95%CI)	P-value	N/Events	HR(95%CI)	P-value	HR(95%CI)	P-value
All patients
Univariate	573/91	1.04(1.01–1.06)	0.0012	249/59	1.03(1.00–1.06)	0.0233	244/36	1.02(0.96–1.08)	0.5325	1.03(1.02–1.05)	7.59×10−5
Multivariatea	573/91	1.04(1.01–1.07)	0.0053	249/59	1.02(1.00–1.05)	0.0914	244/36	1.07(1.00–1.15)	0.0672	1.03(1.02–1.05)	3.97×10−4
Stage I/II
Univariate	453/48	1.04(1.01–1.07)	0.0134	106/8	1.05(0.99–1.12)	0.0944	192/13	1.09(1.02–1.17)	0.0148	1.05(1.02–1.07)	3.04×10−4
Multivariateb	453/48	1.05(1.01–1.08)	0.0059	106/8	1.07(1.00–1.15)	0.0557	192/13	1.15(1.06–1.25)	0.0013	1.06(1.03–1.09)	3.35×10−5
Stage III/IV
Univariate	120/43	1.03(0.99–1.08)	0.1889	143/51	1.02(0.99–1.06)	0.1429	52/23	0.96(0.83–1.12)	0.6237	1.02(1.00–1.05)	6.69×10−2
Multivariatec	120/43	1.03(0.98–1.09)	0.1844	143/51	1.02(0.99–1.05)	0.2321	52/23	0.95(0.83–1.08)	0.4300	1.02(1.00–1.05)	1.25×10−1

^aAdjusted for sex, age, stage(I–IV) and blood draw time from diagnosis;

^bAdjusted for sex, age, stage(I, I/II, II) and blood draw time from diagnosis;

^cAdjusted for sex, age, stage(III, IV) and blood draw time from diagnosis;